Breaking News Instant updates and real-time market news.

GE

General Electric

$9.98

-0.04 (-0.40%)

, LLY

Eli Lilly

$119.45

1.37 (1.16%)

08:55
02/13/19
02/13
08:55
02/13/19
08:55

Notable open interest changes for February 13th

Tuesday's total option volume of 17.2 million contracts resulted in net open interest growth of 2.83 million calls and 2.63 million puts. General Electric (GE), Eli Lilly (LLY), Elanco Animal Health (ELAN) and Electronic Arts (EA) saw the greatest growth. Top five new positions opened include 51k General Electric (GE) 3/8 weekly 9 puts, 50k General Electric (GE) 3/8 weekly 7 puts, 45k Eli Lilly (LLY) Mar-19 150 puts, 45k Eli Lilly (LLY) Mar-19 150 calls and 38k Elanco Animal Health (ELAN) Mar-19 40 puts.

GE

General Electric

$9.98

-0.04 (-0.40%)

LLY

Eli Lilly

$119.45

1.37 (1.16%)

ELAN

Elanco

$29.33

-0.225 (-0.76%)

EA

Electronic Arts

$102.37

5.1 (5.24%)

  • 14

    Feb

  • 14

    Feb

  • 25

    Feb

  • 18

    May

GE General Electric
$9.98

-0.04 (-0.40%)

02/01/19
WBLR
02/01/19
NO CHANGE
WBLR
Outperform
GE shares hitting $14-$16 'highly feasible' in 6-12 months, says William Blair
William Blair analyst Nicholas Heymann ascribes General Electric's 12% share price rise yesterday following its Q4 results to an "inflection in investor sentiment, not short-covering." He believes this occurred in mid-December after the stock bottomed at $6.66. GE ended 2018 "strongly" with "notably better-than-feared" free cash flow, year-over-year organic Industrial growth of 8% for sales and 4% for orders in Q4, and "slightly positive" net price in 2018 that sequentially improved in the second half, Heymann tells investors in a post-earnings research note titled "Up, Up, and Away: New CEO Accelerating Turnaround Pace; Free Cash Flow Better than Feared; Largest Litigation Resolved." The analyst also believes the turnaround of GE Power "is in the very early innings with the process, timing, and 2019 performance yet to be fully detailed." Despite the lack of 2019 detailed guidance, there is no fundamental case for GE shares to have further downside risk, says Heymann. The company's liquidity is "ample," its original targeted proceeds from asset sales are now being expanded and completed earlier than expected, and unknown risks and litigation are being resolved in line with prior reserves, the analyst contends. He keeps an Outperform rating on General Electric. Heymann continues to believe GE's underlying intrinsic value, assigning no value to Power, is somewhere in the range of $14- $16 per share. The analyst sees this range as a "highly feasible base case valuation" for GE's share price over the next 6-12 months. GE closed yesterday at $10.16 per share.
02/01/19
JPMS
02/01/19
NO CHANGE
Target $6
JPMS
Neutral
JPMorgan's Tusa views GE stock rally as head scratcher, keeps $6 price target
In a post-earnings research note titled "The Math Still Matters," JPMorgan analyst Stephen Tusa says he came away from the General Electric's Q4 scratching his head at the stock reaction. Shares of GE closed yesterday up 12%, or $1.06, to $10.16. The analyst attributes the rally to the company's "incrementally better" free cash flow, the "nominal nature" of the Q4 insurance charge, and credibility of the CEO. However, Tusa views the key aspect as more clarity on de-leveraging around where the "value" of the assets is going, and then the "ongoing lack of visibility on the simple math that shows a negative run rate" on enterprise free cash flow fully diluted for portfolio moves. Even assuming recovery in Power, "one has to make highly optimistic assumptions to get back to a run rate that supports anything near $10" per share, Tusa writes. In vowing to "stick to the numbers," Tusa says his read through from GE's Q4 results reaffirms his "well below-consensus model." Overall, "there was a lack of tangible details on key items," Tusa contends. He keeps a Neutral rating on General Electric with a $6 price target.
02/01/19
UBSW
02/01/19
NO CHANGE
Target $12
UBSW
Buy
General Electric turnaround in early stages, says UBS
UBS analyst Peter Lennox-King noted that General Electric's Q4 results were weak, but said that was of less importance than other key issues. He believes the company is in the early stages of a turnaround and that renewables is positioned well on revenue into the PTC expiration. Lennox-King reiterated his Buy rating and $12 price target on General Electric shares.
02/01/19
RBCM
02/01/19
NO CHANGE
Target $12
RBCM
Outperform
General Electric price target raised to $12 from $10 at RBC Capital
RBC Capital analyst Deane Dray raised his price target on General Electric to $12 and kept his Outperform rating, saying the angst about its "liquidity shortfall or fire sale" on its best assets has been "quelled" by its Q4 results. The analyst notes that CEO Larry Culp has acknowledged that the turnaround map for the company is "not yet complete", but he sees the "lack of negatives" in the quarter as a positive. Dray also points to General Electric's seasonally strong free cash flows, adding that its next catalyst should be the upcoming analyst meeting.
LLY Eli Lilly
$119.45

1.37 (1.16%)

01/23/19
UBSW
01/23/19
INITIATION
Target $131
UBSW
Buy
Eli Lilly initiated with a Buy at UBS
UBS analyst Navin Jacob started Eli Lilly with a Buy rating and $131 price target. The analyst's analysis suggests the company's diabetes franchise growth, Verzenio adjuvant trial success and operating margin expansion are not fully appreciated in the stock or estimates
01/18/19
WBLR
01/18/19
DOWNGRADE
WBLR
Market Perform
Loxo Oncology downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Loxo Oncology (LOXO) to Market Perform citing the likelihood of the takeover by Eli Lilly (LLY) closing at the agreed upon price.
01/18/19
JPMS
01/18/19
NO CHANGE
JPMS
Overweight
Eli Lilly trial miss a 'moderate setback,' says JPMorgan
JPMorgan analyst Chris Schott calls Eli Lilly's Phase 3 trial miss of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma a "moderate" setback.
01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.
ELAN Elanco
$29.33

-0.225 (-0.76%)

01/15/19
01/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. StoneCo (STNE) initiated with a Buy at BofA/Merrill. 2. Southwest Gas (SWX) initiated with a Market Perform at Wells Fargo. 3. Luna Innovations (LUNA) initiated with a Buy at B. Riley FBR. 4. Dell Technologies (DELL) initiated with a Neutral at UBS. 5. Elanco (ELAN) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/19
UBSW
01/23/19
INITIATION
Target $29
UBSW
Sell
Elanco initiated with a Sell at UBS
UBS analyst Navin Jacob started Elanco Animal Health with a Sell rating and $29 price target. The company has solid fundamentals, but the stock price and long-term consensus estimates are "too far ahead" of what survey work suggests, Jacob tells investors in a research note.
02/11/19
WBLR
02/11/19
INITIATION
WBLR
Market Perform
Elanco initiated with a Market Perform at William Blair
William Blair analyst John Kreger started Elanco Animal Health with a Market Perform rating.
02/12/19
02/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Viavi (VIAV) initiated with an Outperform at Northland. 2. CECO Environmental (CECE) initiated with a Buy at B. Riley FBR. 3. Tencent Music (TME) initiated with an Outperform at Macquarie. 4. Enable Midstream (ENBL) initiated with a Neutral at Mizuho. 5. Elanco (ELAN) initiated with a Market Perform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EA Electronic Arts
$102.37

5.1 (5.24%)

02/13/19
SPHN
02/13/19
NO CHANGE
Target $57
SPHN
Overweight
Activision Blizzard transition year creates buying opportunity, says Stephens
Stephens analyst Jeff Cohen noted that Activision Blizzard (ATVI), like peers Electronic Arts (EA) and Take-Two (TTWO), gave 2019 guidance that was significantly below consensus and framed it as a transition year. Cohen, who said he feels confident now is the time to be buying as 2019 should represent the trough of earnings power, lowered his price target on the shares to $57 from $65 but keeps an Overweight rating on Activision Blizzard shares.
02/13/19
RHCO
02/13/19
NO CHANGE
Target $49
RHCO
Buy
Activision Blizzard price target lowered to $49 from $54 at SunTrust
SunTrust analyst Matthew Thornton lowered his price target on Activision Blizzard (ATVI) to $49, saying the company's reported quarter and guidance were "clearly challenged", with added risk coming from the rising popularity of Electronic Arts' (EA) Apex Legends. The analyst also keeps his Buy rating on the stock, noting that some of its uncertainty has been removed while the management is increasing development investment to accelerate new content. Thornton lowers his FY19 and FY20 EPS by 42c and 43c to $2.25 and $2.50 respectively, adding that his new valuation multiples are in in with historical average and may prove conservative.
02/11/19
BARD
02/11/19
NO CHANGE
Target $106
BARD
Outperform
Electronic Arts price target raised to $106 from $90 at Baird
Baird analyst Colin Sebastian raised his price target on Electronic Arts to $106 and kept his Outperform rating after the company disclosed today that the number of active Apex Legends players has topped 25M since its launch. The analyst states that the launch implies a better start the the "phenom" Fortnite game, which took over 40 days to reach 25M users, adding that while the data on player retention and monetization is limited, an upcoming update from Respawn should give investors more visibility on whether Apex will be a hit.
02/11/19
02/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Canaccord with analyst Jed Dorsheimer saying he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. 2. Avis Budget (CAR) upgraded to Buy from Sell at Goldman Sachs with analyst David Tamberrino saying trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion. 3. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing the surprise start to Apex Legends' new Battle Royale. 4. Hasbro (HAS) upgraded to Buy from Neutral at Monness Crespi. 5. Lloyds Banking (LYG) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TWTR

Twitter

$31.70

0.94 (3.06%)

16:38
02/22/19
02/22
16:38
02/22/19
16:38
Hot Stocks
Twitter board member Evan Williams to step down at end of month »

On February 22, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

ALLY

Ally Financial

$26.95

-0.07 (-0.26%)

16:34
02/22/19
02/22
16:34
02/22/19
16:34
Hot Stocks
Ally Financial CEO sells over 97,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.